OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation

About this update from Ose Immunotherapeutics Sa

[{"type":"image","alt":"OSE Immunotherapeutics","displaySize":"","headline":null,"caption":"OSE Immunotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h55Oot7mWh39J7Yvj1GueA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb","width":300,"height":100}},"lazy":false},{"type":"text","content":"OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation","length":98,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Completion of Tedopi’s phase 3 in Non-Small Cell Lung Cancer ","length":60,"tagName":"p"}]},{"val":[{"type":"text","content":"One or two new rare/specialty indications for Lusvertikimab","length":59,"tagName":"p"}]},{"val":[{"type":"text","content":"Subcutaneous formulation and combination strategies for Lusvertikimab in UC","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"Management webcast on Wednesday, December 10th at 6pm CET","length":57,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":251,"olType":false},{"type":"text","content":"Nantes, France, December 9, 2025 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced its new three-year strategic plan designed to accelerate development of its most promising programs while maintaining financial discipline. This plan creates multiple near-term catalysts and reinforces OSE Immunotherapeutics’ commitment to immunology innovation.","length":386,"tagName":"p"},{"type":"text","content":"Four Value Creating Opportunities ","length":33,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Complete Tedopi’s Artemia Phase 3 Trial at Limited Cost: The Tedopi® Pivotal Phase 3 in Non-Small Cell Lung Cancer (NSCLC) is progressing as planned with a futility analysis expected in the Q3 2026 and a full read-out in Q1 2028. The completion of this clinical trial will require limited additional financial resources from OSE and ongoing investigator-led Phase 2 studies could also add additional proof-of-concept data at minimal cost.","length":438,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"...

More updates from Ose Immunotherapeutics Sa